GlaxoSmithKline plc with ticker (LON:GSK) now has a potential downside of -10.3% according to Deutsche Bank.
Deutsche Bank set a target price of 1,350 GBX for the company, which when compared to the GlaxoSmithKline plc share price of 1,490 GBX at opening today (29/10/2021) indicates a potential downside of -10.3%. Trading has ranged between 1,191 (52 week low) and 1,529 (52 week high) with an average of 7,634,788 shares exchanging hands daily. The market capitalisation at the time of writing is £75,425,827,570.
GlaxoSmithKline PLC is a global healthcare company. The Company operates through two segments: Pharmaceuticals and Vaccines. The Company focuses on its research across six areas: Respiratory diseases, human immunodeficiency virus (HIV)/infectious diseases, Vaccines, Immuno-inflammation, Oncology and Rare diseases. The Company makes a range of prescription medicines and vaccines products. The Pharmaceuticals business discovers, develops and commercializes medicines to treat a range of acute and chronic diseases. The Vaccines business provides vaccines for people of all ages from babies and adolescents to adults and older people. It has a portfolio of medicines in respiratory and HIV. Its Pharmaceuticals business includes Respiratory, HIV, Specialty products, and Classic and Established products. Its Vaccines business has a portfolio of over 40 pediatric, adolescent, adult, older people and travel vaccines.
GlaxoSmithKline plc -10.3% potential downside indicated by Deutsche Bank
- Written by: Anthony Fox
Find more news, interviews, share price & company profile here for:
GSK's Penmenvy vaccine wins FDA approval, offering protection for ages 10-25 against five major meningococcal serogroups, aiming to boost vaccination rates.
GSK plc reports robust 2024 performance with strong Specialty Medicines growth, promising R&D advancements, and strategic shareholder returns.
GSK's depemokimab, an ultra-long-acting biologic, is up for regulatory review in China and Japan for asthma and CRSwNP, based on positive trial results.
GSK's innovative prefilled Shingrix syringe gains EMA review, aiming to simplify shingles prevention for healthcare professionals across Europe.
GSK's Jemperli plus chemotherapy gains EU approval for broader use in first-line treatment of advanced or recurrent endometrial cancer, improving survival rates.
GSK's Shingrix aims for FDA-approved prefilled syringe to simplify shingles vaccination, enhancing convenience for healthcare providers.
